Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Sees Large Increase in Short Interest

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSGet Rating) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 548,000 shares, a growth of 35.4% from the March 15th total of 404,600 shares. Based on an average daily volume of 38,600 shares, the short-interest ratio is currently 14.2 days. Currently, 5.7% of the company’s shares are short sold.

Tarsus Pharmaceuticals stock opened at $18.38 on Monday. The business’s fifty day moving average is $17.51. The stock has a market capitalization of $380.63 million, a price-to-earnings ratio of -25.53 and a beta of 2.33. Tarsus Pharmaceuticals has a twelve month low of $14.41 and a twelve month high of $39.08.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating) last issued its quarterly earnings data on Monday, March 14th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 7.66% and a negative net margin of 24.25%. The firm had revenue of $0.34 million during the quarter, compared to analyst estimates of $7.11 million. On average, equities research analysts predict that Tarsus Pharmaceuticals will post -3.97 EPS for the current year.

A number of brokerages recently issued reports on TARS. Zacks Investment Research upgraded Tarsus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 24th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, March 17th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $45.80.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 1.7% during the 4th quarter. BlackRock Inc. now owns 448,958 shares of the company’s stock valued at $10,101,000 after purchasing an additional 7,338 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 6.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 28,103 shares of the company’s stock valued at $632,000 after purchasing an additional 1,623 shares during the last quarter. State Street Corp lifted its holdings in shares of Tarsus Pharmaceuticals by 2.3% during the 4th quarter. State Street Corp now owns 129,742 shares of the company’s stock valued at $2,919,000 after purchasing an additional 2,940 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 125,815 shares of the company’s stock valued at $2,830,000 after purchasing an additional 2,117 shares during the last quarter. Finally, Ensign Peak Advisors Inc lifted its holdings in shares of Tarsus Pharmaceuticals by 21.2% during the 4th quarter. Ensign Peak Advisors Inc now owns 242,451 shares of the company’s stock valued at $5,456,000 after purchasing an additional 42,451 shares during the last quarter. Hedge funds and other institutional investors own 69.23% of the company’s stock.

About Tarsus Pharmaceuticals (Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Further Reading

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.